Company / R&D per Share
NEKTAR THERAPEUTICS R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$9.47
FY2025
5-year range
$0.60 / $9.47
FY2021-FY2025
Trend
+1488.2%
vs FY2024
Sector context
#18 of 208
Health Care
What the data says
R&D per Share changed +1488% YoY in FY2025, a notable deviation from the 9-year average annual change of +172%.
Based on SEC 10-K filings.
9.47 in FY2025 with a 5-year CAGR of +33.2%. Top quartile in the Health Care sector.
Improved from $2.12 to $9.47 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +100.4%
- 5-Year CAGR
- +33.2%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 208This company $9.47 Sector average $12.19
▼
-22.3% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 1488.2% year-over-year.
- Ranks #18 out of 208 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -11.97 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.47 | +1488.2% |
| FY2024 | $0.60 | -71.9% |
| FY2023 | $2.12 | +80.3% |
| FY2022 | $1.18 | -47.0% |
| FY2021 | $2.22 | -1.8% |
| FY2020 | $2.26 | +46.3% |
| FY2019 | $1.55 | +21.1% |
| FY2018 | $1.28 | -27.1% |
| FY2017 | $1.75 | +60.5% |
| FY2016 | $1.09 | -21.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026